Bharat Book

Cystic Fibrosis - Pipeline Review, H2

Press Release   •   Dec 04, 2013 10:19 IST

Dec 04, 2013 : Bharat Book Bureau presents the new report, on 'Cystic Fibrosis - Pipeline Review, H2 2013'  provides an overview of the indication’s therapeutic pipeline. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Cystic Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Cystic Fibrosis.
- A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
GlaxoSmithKline plc
Gilead Sciences, Inc.
Vectura Group plc
Novartis AG
Axcan Pharma Inc.
Chiesi Farmaceutici SpA
Pfizer Inc.
Vertex Pharmaceuticals Incorporated
Zambon Group S.p.A.
Optimer Pharmaceuticals, Inc.
PARI Pharma GmbH
Hollis-Eden Pharmaceuticals, Inc.
Pharmaxis Ltd.
CSL Limited
Protalix BioTherapeutics, Inc.
Lipoxen PLC
Galapagos NV
Kamada Ltd.
Proteo, Inc.
Novabiotics Ltd
Nostrum Pharmaceuticals, LLC
Pulmatrix, Inc.
PTC Therapeutics, Inc.
Theraclone Sciences, Inc.
Polyphor Ltd.
Concert Pharmaceuticals, Inc.
ISM Therapeutics
NanoBio Corporation
CBio Limited
Lantibio, Inc.
Ancora Pharmaceuticals Inc.
Morria Biopharmaceuticals Plc
Proteostasis Therapeutics, Inc.
Northern Therapeutics, Inc.
Oceana Therapeutics, Inc.
Savara, Inc.
DiscoveryBiomed, Inc.
Beech Tree Labs, Inc.
N30 Pharmaceuticals
Errant Gene Therapeutics, LLC
AlgiPharma AS
Celtaxsys, Inc.

Table of contents :

Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cystic Fibrosis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Cystic Fibrosis 11
Cystic Fibrosis Therapeutics under Development by Companies 13
Cystic Fibrosis Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Cystic Fibrosis Therapeutics - Products under Development by Companies 24
Cystic Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 28
Companies Involved in Cystic Fibrosis Therapeutics Development 29
Genzyme Corporation 29
Johnson & Johnson 30
Boehringer Ingelheim GmbH 31
GlaxoSmithKline plc 32
Gilead Sciences, Inc. 33
Vectura Group plc 34
Novartis AG 35
Axcan Pharma Inc. 36
Chiesi Farmaceutici SpA 37
Pfizer Inc. 38
Vertex Pharmaceuticals Incorporated 39
Zambon Group S.p.A. 40
Optimer Pharmaceuticals, Inc. 41
PARI Pharma GmbH 42
Hollis-Eden Pharmaceuticals, Inc. 43
Pharmaxis Ltd. 44
CSL Limited 45
Protalix BioTherapeutics, Inc. 46
Lipoxen PLC 47
Galapagos NV 48
Kamada Ltd. 49
Proteo, Inc. 50
Novabiotics Ltd 51
Nostrum Pharmaceuticals, LLC 52
Pulmatrix, Inc. 53
PTC Therapeutics, Inc. 54
Theraclone Sciences, Inc. 55
Polyphor Ltd. 56
Concert Pharmaceuticals, Inc. 57
ISM Therapeutics 58

For more information kindly visit :

Related link :


About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.